Navidea Biopharmaceuticals Posts Lymphoseek® NDA Update to Company Website

Published: Oct 11, 2012

DUBLIN, Ohio--(BUSINESS WIRE)--Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB), a biopharmaceutical company focused on the development and commercialization of precision diagnostics and radiopharmaceutical agents, today posted on its website an update to the status of the Lymphoseek NDA review. The web access to the statement can be found on the Navidea Investor page at: Contacts

Navidea Biopharmaceuticals

Brent Larson, 614-822-2330

Sr. VP & CFO

Back to news